QUALITY OF LIFE

Patients Taking ALUNBRIG® (brigatinib) Reported Better Quality of Life1

Secondary Endpoint: ALUNBRIG delayed time to worsening in Global Health Status (GHS)/Quality of Life (QoL)1

Median Time to Worsening in GHS/QoL (≥10-Point Worsening Score)1,a

Median Time to Worsening in GHS/QoL (≥10-Point Worsening Sore)¹,a

Study Limitations: These patient-reported outcome (PRO) endpoints were exploratory and not prespecified. The improvement in QoL scores and delay in worsening of GHS/QoL may be an overestimation, because patients were not blinded to treatment assignment.

  • Analysis of PRO measures was supported by multiple functional scales (including physical, emotional, and social) and multiple symptom scales (including fatigue, nausea and vomiting, appetite loss and constipation)2
  • These differences in global QoL could reflect differences in efficacy on disease-related symptoms and in treatment-related adverse events1

Duration of Improvement Among Responders

Among responders, the median duration of improvement in QoL had not been reached for ALUNBRIG vs 12 months for crizotinib.1

aPatient-reported symptoms, functioning, and global health status (GHS)/quality of life (QoL) were measured using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and supplemental QLQ-LC13 (Lung Cancer Module).1

View the ALTA 1L Clinical Trial Results

References

  1. Camidge DR, Kim HR, Ahn MJ, et al. J Clin Oncol. 2020; available at: https://www.ascopubs.org/doi/full/10.1200/JCO.20.00505. Accessed August 13, 2020.
  2. ARIAD Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Data on file.

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

Takeda Oncology makes no representation as to the accuracy of the information contained on sites we do not own or control. Takeda Oncology does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Cancel Continue +

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

This link will take you to the corporate ARIAD Pharmaceuticals, Inc. website.

Cancel Continue
Close

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib).

This link will take you to another Takeda Oncology website.

Cancel Continue +

The site you are about to enter is intended for US healthcare professionals only.

Please confirm that you are a US healthcare professional.

Yes, I confirm that I am a US healthcare professional Cancel +

In Vitro: ALUNBRIG Inhibited 17
ALK-Inhibitor-Resistant Mutations1,2

ALUNBRIG exhibited in vivo antitumor activity against 4 mutant forms of EML4-ALK, including the G1202R and L1196M mutants identified in NSCLC tumors in patients who had progressed on crizotinib.


 

We use cookies to gather web statistics that help us improve our site. We store no personal details.
ACCEPT

Read More